Eribulin + Olaparib Combination Therapy

The combination of eribulin and olaparib is being investigated as a treatment for triple-negative breast cancer (TNBC), particularly in patients previously treated with anthracyclines and taxanes. This combination therapy shows promising antitumor activity, though caution must be exercised due to potential side effects such as febrile neutropenia. Eribulin is a microtubule inhibitor that works by destabilizing microtubule dynamics, leading to mitotic arrest and subsequent abnormal mitotic divisions. It is considered a global standard drug for advanced TNBC after treatment with anthracyclines and taxanes. Olaparib is a PARP (poly ADP-ribose polymerase) inhibitor that has shown efficacy against various solid tumors. When combined with eribulin, olaparib appears to enhance eribulin-induced cell cycle arrest at the G2/M boundary. The combination results in enhanced PARP3 inhibition compared to either drug alone, greater disruption of microtubule dynamics, increased chromosome misalignment, more pronounced mitotic catastrophe effects, and potentiated cell cycle arrest. A phase I/II trial (UMIN000009498) was conducted to evaluate this combination in Japanese patients with advanced or metastatic TNBC who had previously received anthracyclines and taxanes. The trial used a traditional 3+3 design, with eribulin administered intravenously and olaparib orally. Research suggests that BRCA1 promoter methylation status may be associated with response to this combination therapy. Patients with BRCA1 or BRCA2 mutations, or high BRCA1 promoter methylation, showed better 6-month progression-free survival. Quantitative methylation analysis may help identify TNBC patients who would benefit. The combination appears to be effective regardless of estrogen receptor (ER) status in breast cancer cells, suggesting broader potential applications beyond TNBC.